Choice of opioids and the WHO ladder

Journal of Pediatric Hematology/Oncology

Volumn 33, Issue SUPPL. 1, 2011, Pages

  Glare, Paul ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

opioids; pain management; palliative care; WHO

Indexed keywords

BUPRENORPHINE; CODEINE; DEXTROPROPOXYPHENE; FENTANYL; HYDROMORPHONE; METHADONE; MORPHINE; MORPHINE 6 GLUCURONIDE; NALBUPHINE; NONSTEROID ANTIINFLAMMATORY AGENT; OPIATE; OXYCODONE; PARACETAMOL; PENTAZOCINE; PHENANTHRENE; TRAMADOL; NARCOTIC ANALGESIC AGENT;

ARTICLE; CANCER PAIN; CARDIOTOXICITY; COMMUNITY; CULTURAL ANTHROPOLOGY; DEVELOPING COUNTRY; DRUG BIOAVAILABILITY; DRUG CHOICE; DRUG DEPENDENCE; HEALTH SERVICE; HOSPITAL; HUMAN; LOW DRUG DOSE; MIDDLE EAST; OPIOPHOBIA; PALLIATIVE THERAPY; PHOBIA; PHYSICIAN ATTITUDE; POLICY; PRACTICE GUIDELINE; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE; RELIGION; WORLD HEALTH ORGANIZATION; ETHNOLOGY; METHODOLOGY; PATIENT COMPLIANCE; PATIENT EDUCATION; PHYSICIAN; PSYCHOLOGICAL ASPECT; REVIEW; TREATMENT REFUSAL;

ANALGESICS, OPIOID; DEVELOPING COUNTRIES; HUMANS; PALLIATIVE CARE; PATIENT COMPLIANCE; PATIENT EDUCATION AS TOPIC; PHYSICIANS; TREATMENT REFUSAL; WORLD HEALTH ORGANIZATION;

EID: 79954995194     PISSN: 10774114     EISSN: 15363678     Source Type: Journal    
DOI: 10.1097/MPH.0b013e3182121a2b     Document Type: Article

References (67)

1. Foley KM. The treatment of cancer pain. N Engl J Med. 1985; 313:84-95. (Pubitemid 15068702)
2. Bonica JJ. Cancer Pain. In: Bonica JJ. ed. The Management of Pain. Philadelphia: Lea and Feabiger; 1990:437.
3. Foley KM. Controversies in cancer pain: medical perspectives. Cancer. 1989;63:2257-2265. (Pubitemid 19141071)
4. Melzack R, Ofiesh JG, Mount BM. The Brompton mixture: effects on pain in cancer patients. Can Med Assoc J. 1976;115: 125-129.
5. Melzack R, Mount BM, Gordon JM. The Brompton mixture versus morphine solution given orally: effects on pain. Can Med Assoc J. 1979;120:435-438.
6. Black P. Management of cancer pain: an overview. Neurosurgery. 1979;5:507-518.
7. Cancer Pain Relief and Palliative Care. Geneva: World Health Organization; 1990. Report No.: Technical Report Series 804.
8. Jacox AK, Carr DB, Payne R. Clinical Practice Guideline Number 9: Management of Cancer Pain. Dept of Health and Human Services AfHCPaR. Rockville. MD: 1994.
9. Hanks GW, Conno F, Cherny N, et al. Morphine and alternative opioids in cancer pain: the EAPC recommendations. Br J Cancer. 2001;84:587-593. (Pubitemid 32238990)
10. Morphine in cancer pain: modes of administration. Expert Working Group of the European Association for Palliative Care. BMJ. 1996;312:823-826.
11. Swarm R, Abernethy AP, Anghelescu DL, et al. Adult cancer pain. J Natl Compr Canc Netw. 2010;8:1046-1086.
12. Shamieh O, Jazieh A-R. Modification and implementation of NCCN guidelines on palliative care in the Middle East and North Africa region. JNCCN. 2010;8:s41-ss47.
13. Cancer Pain Relief. Geneva: World Health Organization; 1986.
14. Ventafridda V, Tamburini M, Caraceni A, et al. A validation study of the WHO method for cancer pain relief. Cancer. 1987;59:850-856. (Pubitemid 17018769)
15. Walker VA, Hoskin PJ, Hanks GW, et al. Evaluation of WHO analgesic guidelines for cancer pain in a hospital-based palliative care unit. J Pain Symptom Manage. 1988;3:145-149.
16. Goisis A, Gorini M, Ratti R, et al. Application of a WHO protocol on medical therapy for oncologic pain in an internal medicine hospital. Tumori. 1989;75:470-472. (Pubitemid 20064228)
17. Ventafridda V, Caraceni A, Gamba A. Field-testing of the WHO guidelines for cancer pain relief. In: Foley KM, Bonica JJ, Ventafridda V, et al. eds. Second International Congress on Cancer Pain. New York: Raven Press; 1990:451-464.
18. Takeda F. Japan's WHO cancer pain relief program. In: Foley KM, Bonica JJ, Ventafridda V, et al. eds. Second International Congress on Cancer Pain. New York: Raven Press; 1990: 475-483.
19. Wenk R, Diaz C, Echeverria M, et al. Argentina's WHO Cancer Pain Relief Program: a patient care model. J Pain Symptom Manage. 1991;6:40-43.
20. Siguan SS, Damole AA, Mejarito AG. Results of cancer pain treatment at Southern Islands Medical Center, Cebu, Philippines. Philipp J Surg Spec. 1992;47:173-176.
21. Zech DF, Grond S, Lynch J, et al. Validation of World Health Organization Guidelines for cancer pain relief: a 10-year prospective study. Pain. 1995;63:65-76.
22. Jadad AR, Browman GP. The WHO analgesic ladder for cancer pain management: stepping up the quality of its evaluation. JAMA. 1995;274:1870-1873. (Pubitemid 26001265)
23. Ashby MA, Fleming BG, Brooksbank M, et al. Description of a mechanistic approach to pain management in advanced cancer: preliminary report. Pain. 1992;51:153-161. (Pubitemid 23000730)
24. Du Pen SL, Du Pen AR, Polissar N, et al. Implementing guidelines for cancer pain management: results of a randomized controlled clinical trial. J Clin Oncol. 1999;17:361-370. (Pubitemid 29022415)
25. Abernethy AP, Samsa GP, Matchar DB. A clinical decision and economic analysis model of cancer pain management. Am J Manag Care. 2003;9:651-664. (Pubitemid 37345194)
26. Lickiss JN. Approaching cancer pain relief. Eur J Pain. 2001; 5(suppl A):5-14.
27. Deandrea S, Montanari M, Moja L, et al. Prevalence of undertreatment in cancer pain: a review of published literature. Ann Oncol. 2008;19:1985-1991.
28. Glare P, Aggarwal G, Clark K. Ongoing controversies in the pharmacological management of cancer pain. Intern Med J. 2004;34:45-49. (Pubitemid 38293696)
29. Davis MP, Walsh D, Lagman R, et al. Controversies in pharmacotherapy of pain management. Lancet Oncol. 2005;6: 696-704. (Pubitemid 41222760)
30. SAMHSA. Results From the 2001 National Household Survey on Drug Abuse: Volume I. Summary of National Findings. Studies SAaMHSAOoA. Rockville, Md: DHHS; 2002.
31. Clines FX, Meier B. Cancer Painkillers Pose New Abuse Threat. NY Times; 2001.
32. Eisenberg E, Berkey CS, Carr DB, et al. Efficacy and safety of nonsteroidal antiinflammatory drugs for cancer pain: a metaanalysis. J Clin Oncol. 1994;12:2756-2765. (Pubitemid 24379666)
33. Organ-Specific Warnings; Internal Analgesic, Antipyretic, and Antirheumatic Drug Products for Over-the-Counter Human Use; Final Monograph. In: HHS FaDA, ed.; 2009:25.
34. Moore A, Collins S, Carroll D, et al. Paracetamol with and without codeine in acute pain: a quantitative systematic review. Pain. 1997;70:193-201. (Pubitemid 27179631)
35. De Conno F, Ripamonti C, Sbanotto A, et al. A clinical study on the use of codeine, oxycodone, dextropropoxyphene, buprenorphine, and pentazocine in cancer pain. J Pain Symptom Manage. 1991;6:423-427.
36. Smith HS. Opioid metabolism. Mayo Clin Proc. 2009;84: 613-624.
37. Trescot AM. Review of the role of opioids in cancer pain. J Natl Compr Canc Netw. 2010;8:1087-1094.
38. Cicero TJ, Surratt H, Inciardi JA, et al. Relationship between therapeutic use and abuse of opioid analgesics in rural, suburban, and urban locations in the United States. Pharmacoepidemiol Drug Saf. 2007;16:827-840. (Pubitemid 47322580)
39. Xanodyne agrees to withdraw propoxyphene from the U.S. market. In: FDA NEWS RELEASE; 2010.
40. Marinangeli F, Ciccozzi A, Leonardis M, et al. Use of strong opioids in advanced cancer pain: a randomized trial. J Pain Symptom Manage. 2004;27:409-416. (Pubitemid 38569646)
41. Krakowski I, Theobald S, Balp L, et al. Summary version of the Standards, Options and Recommendations for the use of analgesia for the treatment of nociceptive pain in adults with cancer (update 2002). Br J Cancer. 2003;89(suppl 1):S67-72. (Pubitemid 37076151)
42. Hardy JR, Nauck F. Opioids for cancer pain. In: Walsh D. ed. Palliative Medicine. Philadelphia: Elsevier; 2008:1404-11.
43. Davis MP. Cancer pain. In: Olver IN. ed. The MASCC textbook of cancer supportive care and survivorship. New York: Springer; 2010:11-22.
44. Wiffen PJ, McQuay HJ. Oral morphine for cancer pain. Cochrane Database Syst Rev. 2007;CD003868.
45. Andersen G, Christrup L, Sjogren P. Relationships among morphine metabolism, pain and side effects during long-term treatment: an update. J Pain SymptomManage. 2003;25:74-91. (Pubitemid 36143654)
46. McQuay H. Opioids in pain management. Lancet. 1999;353: 2229-2232. (Pubitemid 29295264)
47. Reid CM, Gooberman-Hill R, Hanks GW. Opioid analgesics for cancer pain: symptom control for the living or comfort for the dying? A qualitative study to investigate the factors influencing the decision to accept morphine for pain caused by cancer. Ann Oncol. 2008;19:44-48.
48. Bell RF, Wisloff T, Eccleston C, et al. Controlled clinical trials in cancer pain: How controlled should they be? A qualitative systematic review. Br J Cancer. 2006;94:1559-1567. (Pubitemid 43924913)
49. Bruera E, Palmer JL, Bosnjak S, et al. Methadone versus morphine as a first-line strong opioid for cancer pain: a randomized, double-blind study. J Clin Oncol. 2004;22: 185-192. (Pubitemid 41095131)
50. Ross JR, Rutter D, Welsh K, et al. Clinical response to morphine in cancer patients and genetic variation in candidate genes. Pharmacogenomics J. 2005;5:324-336. (Pubitemid 41486231)
51. Reyes-Gibby CC, Shete S, Rakvag T, et al. Exploring joint effects of genes and the clinical efficacy of morphine for cancer pain: OPRM1 and COMT gene. Pain. 2007;130:25-30. (Pubitemid 46850782)
52. Mercadante S. Opioid titration in cancer pain: a critical review. Eur J Pain. 2007;11:823-830. (Pubitemid 47321243)
53. Amabile CM, Bowman BJ. Overview of oral modified-release opioid products for the management of chronic pain. Ann Pharmacother. 2006;40:1327-1335. (Pubitemid 44204963)
54. Dean M. Opioids in renal failure and dialysis patients. J Pain Symptom Manage. 2004;28:497-504. (Pubitemid 39422488)
55. Heiskanen T, Matzke S, Haakana S, et al. Transdermal fentanyl in cachectic cancer patients. Pain. 2009;144:218-222.
56. Mercadante S, Villari P, Ferrera P. Itraconazole-fentanyl interaction in a cancer patient. J Pain Symptom Manage. 2002; 24:284-286.
57. Horton R, Barber C. Opioid-induced respiratory depression resulting from transdermal fentanyl-clarithromycin drug interaction in a patient with advanced COPD. J Pain Symptom Manage. 2009;37:e2-e5.
58. Essandoh S, Sakae M, Miller J, et al. A cautionary tale from critical care: resolution of myoclonus after fentanyl rotation to hydromorphone. J Pain Symptom Manage. 2010;40:e4-e6.
59. Krantz MJ, Martin J, Stimmel B, et al. QTc interval screening in methadone treatment. Ann Intern Med. 2009;150:387-395.
60. Szeto HH, Inturrisi CE, Houde R, et al. Accumulation of normeperidine, an active metabolite of meperidine, in patients with renal failure of cancer. Ann Intern Med. 1977;86:738-741. (Pubitemid 8118769)
61. Substance Abuse Issues In Cancer (PDQ) In: National Cancer Institute; 2008.
62. Fainsinger RL, Thai V, Frank G, et al. What's in a word? Addiction versus dependence in DSM-V. Am J Psychiatry. 2006;163:2014.
63. Passik SD, Messina J, Golsorkhi A, et al. Aberrant Drug-Related Behavior Observed During Clinical Studies Involving Patients Taking Chronic Opioid Therapy for Persistent Pain and Fentanyl Buccal Tablet for Breakthrough Pain. J Pain Symptom Manage. 2010. [Epub ahead of print].
64. Fisher FB. Interpretation of "Aberrant" Drug-Related Behaviors. J Am Phys Surg. 2004;9:25-28.
65. Gfroerer J, Brodsky M. The incidence of illicit drug use in the United States, 1962-1989. Br J Addict. 1992;87:1345-1351.
66. Weissman DE, Haddox JD. Opioid pseudoaddiction-an iatrogenic syndrome. Pain. 1989;36:363-366.
67. Stauffer J, Setnik B, Sokolowska M, et al. Subjective effects and safety of whole and tampered morphine sulfate and naltrexone hydrochloride (ALO-01) extended-release capsules versus morphine solution and placebo in experienced nondependent opioid users: a randomized, double-blind, placebocontrolled, crossover study. Clin Drug Investig. 2009;29: 777-790.